Indoco Remedies Peer Comparison

NSE: INDOCO | BSE: 532612

₹231.50

₹-5.00 (-2.11%)

As on 21-Oct-2026IST

Market cap

₹2,154 Cr

Revenue (TTM)

₹1,873 Cr

P/E Ratio

382.6

P/B Ratio

2.2

Div. Yield

0.1 %

Edit

	Indoco Remedies	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	2,154	33,312	24,341	15,415	13,264
Revenue (₹ Cr)	1,873	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	3.10	1,018.97	497.77	603.02	270.18
Net Margin (%)	0.17	10.47	20.72	22.63	23.29
RoE (%)	-7.59	21.30	28.49	19.61	14.45
Price to Earnings	382.58	32.94	48.90	25.56	48.17
Price-To-Book	2.16	6.37	12.04	4.42	6.40

Income Statement (₹ Cr)

	Indoco Remedies	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	1,873.14	9,683.45	2,371.81	2,590.40	1,108.39
Total Income	1,877.02	9,730.84	2,402.61	2,664.23	1,159.90
Total Expenditure	1,707.85	7,739.53	1,608.91	1,753.71	720.01
EBITDA	165.29	1,943.92	762.90	836.69	388.38
Depreciation	131.28	425.10	98.11	78.88	74.78
EBIT	34.01	1,518.82	664.79	757.81	313.60
Interest	124.41	148.45	26.33	5.43	0.26
Other Income	3.88	47.39	30.80	73.83	51.50
Exceptional Items	94.40	-27.85	0.00	-25.66	-3.28
Profit before Tax	7.88	1,389.91	669.26	800.55	361.56
Provision for Tax	4.78	370.94	171.48	197.53	91.39
Profit after Tax	3.10	1,018.97	497.77	603.02	270.18

	Indoco Remedies	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	939.28	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	2.53	-7.58	0.00	0.00	2.51
Non-Current Liabilities	608.61	723.57	345.47	142.73	50.51
Current Liabilities	1,052.55	3,912.24	710.20	508.04	169.08
Total Liabilities	2,602.59	9,514.48	2,930.14	4,157.10	2,231.79

	Indoco Remedies	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	1,203.78	3,392.16	1,290.62	1,321.38	957.22
Current Assets	1,193.35	5,612.10	1,483.13	2,649.36	1,250.11
Total Assets	2,602.59	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	1,035.84	1,204.08	196.61	0.00	0.00
Net Current Assets	140.80	1,699.86	772.93	2,141.33	1,081.04
Contingent Liabilities	139.58	258.92	13.18	4.82	3.76

	Indoco Remedies	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	192.23	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	-101.61	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	-76.79	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	13.82	93.92	-56.08	-69.08	11.28

	Indoco Remedies	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	0.79	25.25	27.50	24.61	18.04
ROE (%)	-7.59	21.30	28.49	19.61	14.45
ROA (%)	0.12	11.42	19.48	16.31	12.66
EBIT Margin (%)	1.82	15.68	28.03	29.25	28.29
Net Margin (%)	0.17	10.47	20.72	22.63	23.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Indoco Remedies	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	11.96	18.36	78.33	7.93	-6.72
EBIT Growth (%)	172.38	30.43	303.07	19.88	-26.64
Net Profit Growth (%)	102.67	32.39	182.61	21.66	-24.38
EPS Growth (%)	35.57	36.68	277.72	25.42	-21.99
Book Value Growth (%)	-8.21	11.36	22.95	18.43	11.27

	Indoco Remedies	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	-29.56	32.26	48.90	24.75	47.74
Price / Book Value	2.16	6.37	12.04	4.42	6.40
Dividend Yield (%)	0.09	0.21	0.18	0.40	0.60
EV/EBITDA	19.10	17.68	31.70	17.49	33.08
Market Cap (₹ Cr)	1,521.65	30,257.56	15,412.11	11,956.86	10,627.92

	Indoco Remedies	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.55	0.05	0.09	0.00	0.00
Short term debt to equity ratio	0.40	0.16	--	--	--
Current Ratio	1.13	1.43	2.09	5.21	7.39
Quick Ratio	0.75	0.82	1.37	3.85	5.46
Interest Coverage	1.06	10.36	26.41	148.49	1,386.30

	Indoco Remedies	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	26.11	26.46	22.82	41.42	41.52
Asset Turnover	0.75	1.09	0.93	0.70	0.52
Receivable days	83.23	88.68	77.32	144.58	169.86
Inventory Days	81.55	84.11	80.83	96.67	97.92
Payable days	174.05	176.65	125.94	135.45	159.68
Cash Conversion Cycle	-9.27	-3.86	32.22	105.80	108.11

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.